Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: A pharmacoscintigraphic study

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5705-5718

  Alam, Sanjar ^a   Khan, Zeenat I ^a   Mustafa, Gulam ^a   Kumar, Manish ^b   Islam, Fakhrul ^c   Bhatnagar, Aseem ^d   Ahmad, Farhan J ^a  

^a HAMDARD UNIVERSITY   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

^c HAMDARD UNIVERSITY   (India)

^d INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Chitosan; Gamma scintigraphy; Nanoparticles; Nose to brain targeting; Thymoquinone

Indexed keywords

CHITOSAN NANOPARTICLE; NANOPARTICLE; THYMOQUINONE; TRIPOLYPHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN TISSUE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; EX VIVO STUDY; GELATION; LIGHT SCATTERING; MALE; MUCOADHESION; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; RAT; SCINTIGRAPHY; SURFACE PROPERTY; THERMOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

ADMINISTRATION, INTRANASAL; ANIMALS; BENZOQUINONES; BRAIN; CHITOSAN; DIFFUSION; DRUG DESIGN; GOATS; MALE; METABOLIC CLEARANCE RATE; NANOCAPSULES; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 84870367030     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S35329     Document Type: Article

References (45)

1. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137-147.
2. Desgranges B, Baron JC, de la Sayette V, etal. The neural substrates of memory systems impairment in Alzheimer's disease: A PET study of resting brain glucose utilization. Brain. 1998;121:611-631.
3. Forstl H, Hentschel F, Sattel H, etal. Age-associated memory impairment and early Alzheimer's disease. Drug Res. 1995;45(1):394-397.
4. Kumar V, Durai NB, Jobe T. Pharmacologic management of Alzheimer's disease. Clin Geriatr Med. 1998;14(1):129-146.
5. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425-432.
6. Ishrat T, Hoda MN, Khan MB, etal. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol. 2009;19: 636-647.
7. Akhondzadeh S, Abbasi SH. Herbal medicine in the treatment of Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2006;21(2): 113-118.
8. Howesa MR, Houghton PJ. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav. 2003;75:513-527.
9. Al-Majed AA, Al-Omar FA, Nagi MN. Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus. Eur J Pharmacol. 2006;543:40-47.
10. Al-Ghamdi MS. The anti-inflammatory, analgesic and antipyretic activity of Nigella sativa. J Ethnopharmacol. 2001;76:45-48.
11. Mansour MA, Nagi MN, El-Khatib AS, Al-Bekairi AM. Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT-diaphorase in different tissues of mice: a possible mechanism of action. Cell Biochem Funct. 2002;20:143-151.
12. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across blood-brain barrier. Drug Dev Ind Pharm. 2002;28:1-12.
13. Witt KA, Davis TP. CNS drug delivery: Opioid peptides and the blood-brain barrier. AAPS J. 2006;8(1):76-88.
14. Gabriel AS. Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier. Surg Neurol. 2007;67: 113-116.
15. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci. 2002;6(4): 319-327.
16. Illum L. Transport of drugs from the nasal cavity to central nervous system. Eur J Pharm Sci. 2000;11:1-18.
17. Vyas TK, Shahiwala A, Marathe S, Misra A. Intranasal drug delivery for brain targeting. Curr Drug Del. 2005;2:164-175.
18. Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Euro J Pharm Biopharm. 2008;70:735-740.
19. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol. 2001;53: 3-21.
20. Fazil M, Md S, Haque S, etal. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci. 2012;47(1):6-15.
21. Calvo P, Remunan-Lopez C, Vila-Jata JL, Alonso MJ. Chitosan and chitosan: ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res. 1997;14: 1431-1436.
22. Aktas Y, Andrieux K, Alonso MJ, etal. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm. 2005;298:378-383.
23. Ghosheh OA, Houdi AA, Crooks PA. High performance liquid chromatographic analysis of the pharmacologically active quinones and related compounds in the oil of the black seed (Nigella sativa L.). J Pharm Biomed Anal. 1999;19:757-762.
24. Ge H, Hu Y, Jiang X, etal. Preparation, characterization, and drug release behaviors of drug nimodipine-loaded poly(e-caprolactone)-poly(ethylene oxide)-poly(e-caprolactone) amphiphilic triblock copolymer micelles. J Pharm Sci. 2002;91:1463-1473.
25. Babbar AK, Singh AK, Goel HC, Chauhan UPS, Sharma RK. Evaluation of 99mTc labelled Photosan-3, a haematoporphyrin derivative, as a potential radiopharmaceutical for tumor scintigraphy. Nucl Med Biol. 2000;27:419-426.
26. Burits M, Bucar F. Antioxidant activity of Nigella sativa essential oil. Phytother Res. 2000;14(5):323-328.
27. Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm. 2008;358:285-291.
28. Papadimitriou S, Bikiaris D, Avgoustakis K, Karavas E, Georgarakis M. Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym. 2008;73:44-54.
29. Quellec P, Gref R, Perrin L, etal. Protein entrapment within polyethylene glycol-coated nanospheres. I. Physicochemical characterization. J Biomed Mater Res. 1998;42:45-54.
30. Mohanraj VJ, Chen Y. Nanoparticles-A review. Trop J Pharm Res. 2006;5:561-573.
31. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: Preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm. 2010;76:189-199.
32. Pagola S, Benavente A, Raschi A, Romano E, Molina MAA, Stephens PW. Crystal structure determination of thymoquinone by high-resolution X-ray powder diffraction. AAPS PharmSciTech. 2003;5(2):e28.
33. Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Release. 1987;5:37-44.
34. Vllasaliu D, Exposito-Harris R, Heras A, etal. Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int J Pharm. 2010;400(1-2):183-193.
35. Richter T, Keipert S. In vitro permeation studies comparing bovine nasal mucosa, porcine cornea and artificial membrane: androstenedione in microemulsions and their components. Eur J Pharm Biopharm. 2004;58:137-143.
36. Tosi G, Costantino L, Rivasi F, etal. Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release. 2007;122:1-9.
37. Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Bertolini A, Costantino L. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomed Nanotech Biol Med. 2009;5: 369-377.
38. Wang X, He H, Leng W, Tang X. Evaluation of brain-targeting for the nasal delivery of estradiol by the microdialysis method. Int J Pharm. 2006;317:40-46.
39. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127:481-496.
40. Bhavna, Sharma V, Ali M, Baboota S, Ali J. Preparation and characterization of chitosan nanoparticles for nose to brain delivery of a cholinesterase inhibitor. Ind J Pharm Sci. 2007;69(5):712-723.
41. Al-Ghananeem AM, Saeed H, Florence R, Yokel RA, Malkawi AH. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target. 2010;18(5):381-388.
42. Soni S, Kumar BA, Kumar SR, Banerjee T, Maitra A. Pharmacoscintigraphic evaluation of polysorbate 80-coated chitosan nanoparticles for brain targeting. Am J Drug Del. 2005;3(3):205-212.
43. Huo MR, Zhou JP, Wei Y, Lu L. Preparation of paclitaxel-loaded chitosan polymeric micelles and influence of surface charges on their tissue biodistribution in mice. Acta Pharm Sin. 2006;41:867-872.
44. Mahato RI, Kawabata K, Nomura T, Takakura Y, Hashida M. Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes. J Pharm Sci. 1995;84:1267-1271.
45. Zhang Q, Jiang X, Xiang W, Lu W, Su L, Shi Z. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation of the targeting efficiency to brain. Int J Pharm. 2004;275:85-96.